Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that Maxigesic IV is now available in Germany, the largest European pharmaceutical market, and Austria. Maxigesic IV is a novel, patented, non-opioid treatment for post-operative pain and is a unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion. Hyloris’ partner AFT Pharmaceuticals works together with distribution partners with strong local presence to commercialise the product globally. Maxigesic IV is currently licensed in more than 100 countries across the globe, and it has been registered in 24 countries. Following the launch in Germany and Austria, the product is now available in 5 countries: Australia, New Zealand, The United Arab Emirates, Germany, and Austria.